Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study

Romain Mathieu, Tobias Klatte, Vitaly Margulis, Jose A. Karam, Morgan Rouprêt, Christian Seitz, Pierre I. Karakiewicz, Harun Fajkovic, Christopher G. Wood, Alon Z. Weizer, Jay D. Raman, Mesut Remzi, Nathalie Rioux-Leclercq, Andrea Haitel, Karim Bensalah, Yair Lotan, Michael Rink, Luis A. Kluth, Douglas S. Scherr, Brian D. RobinsonShahrokh F. Shariat

Research output: Contribution to journalArticle

7 Scopus citations


Objective: Several small single-center studies have reported conflicting results on the prognostic value of survivin expression in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy. We attempted to validate the prognostic utility of survivin using a large multi-institutional cohort. Material and methods: Survivin expression was evaluated by immunohistochemistry in tumor tissue from 732 patients with unilateral, sporadic UTUC treated with radical nephroureterectomy between 1990 and 2008 at 7 centers. Survivin expression was considered altered when at least 10% of the tumor cells stained positive. Associations of altered survivin expression with recurrence-free survival (RFS) and cancer-specific survival (CSS) were evaluated using Cox proportional hazards regression models. Results: Altered survivin expression was observed in 288 (39.3%) tumors and was associated with more advanced pathological tumor stages ( P

Original languageEnglish (US)
Pages (from-to)495.e15-495.e22
JournalUrologic Oncology: Seminars and Original Investigations
Issue number11
Publication statusPublished - Nov 1 2015



  • Carcinoma
  • Death
  • Recurrence
  • Survivin
  • Urothelium

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this